In the Phase 3 Trial for IgA Nephropathy, Atrasentan was found to be more effective at reducing proteinuria than a placebo.

Published Date: 06 Nov 2023

Clusters of antibodies accumulate in the kidneys as a result of the autoimmune disease known as IgA nephropathy (IgAN), which causes inflammation and renal damage.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care

2.

FDA approves Blenrep for relapsed or refractory multiple myeloma

3.

X-ray and radar technology combined to reduce cancer screening risks

4.

Extended Maintenance with Imatinib Enhances Disease-Free Survival in High-Risk GIST.

5.

Researchers discuss HER2-low and HER2-zero in breast cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot